Thursday, April 9, 2026 – Friday, April 10 - (MedPage Today) -- Integrating the most effective obesity treatments into cancer survivorship offers "an unprecedented opportunity" to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in...
Thursday, April 9, 2026 – Friday, April 10 - The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout
Thursday, April 9, 2026 – Friday, April 10 - Steve Ubl, chief executive of PhRMA, plans to step down at the end of the year, after more than a decade leading the main trade group for brand-name drug makers
Wednesday, April 8, 2026 – Thursday, April 9 - 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.
Wednesday, April 8, 2026 – Thursday, April 9 - Changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs — and whether the drugs will cause nausea or vomiting.
Wednesday, April 8, 2026 – Thursday, April 9 -
Tuesday, April 7, 2026 – Wednesday April 8 - (MedPage Today) -- In a whistleblower lawsuit, a prominent cardiologist says he was fired from the University of Pittsburgh Medical Center (UPMC) after reporting racist text messages exchanged between colleagues and a potential conflict of interest...
Tuesday, April 7, 2026 – Wednesday April 8 - (MedPage Today) -- Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month...
Tuesday, April 7, 2026 – Wednesday April 8 - Plus, news about Vertex and Halozyme, Werewolf, and Regeneron:
Novo Nordisk launches high-dose Wegovy in the US: The 7.2 mg injectable form of the GLP-1 agonist is now available in the US to treat obesity ...
Tuesday, April 7, 2026 – Wednesday April 8 - Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout